Pfizer Recalls All Lots of Chantix Due to Potential Carcinogen
FRIDAY, Sept. 17, 2021 (HealthDay News) -- Pfizer is expanding the recall of its antismoking drug Chantix (varenicline), the company announced Friday.
The nationwide recall of all Chantix 0.5-mg and 1-mg tablets was prompted because they may contain levels of a nitrosamine, N-nitroso-varenicline, that are at or above levels approved by the U.S. Food and Drug Administration.
Long-term ingestion of N-nitroso-varenicline may be linked to a "theoretical potential increased cancer risk in humans," the company said, adding that no immediate risk to patients taking Chantix exists.
"The health benefits of stopping smoking outweigh the theoretical potential cancer risk from the nitrosamine impurity in varenicline," Pfizer said in its statement.
So far, Pfizer has received no reports of adverse events tied to this recall, the company stated.
Related Posts
Many Women Lack Information on Breast Reconstruction After Mastectomy
FRIDAY, Oct. 28, 2022 (HealthDay News) -- Many women may not receive adequate...
Physician’s Briefing Weekly Coronavirus Roundup
Here is what the editors at Physician's Briefing chose as the most important...
New Alzheimer’s Drug Shows Promise in Phase 3 Clinical Trial
WEDNESDAY, Sept. 28, 2022 (HealthDay) -- Japanese drugmaker Eisai on Wednesday...
ACP Issues Final Practice Points for Remdesivir Use in COVID-19
TUESDAY, March 1, 2022 (HealthDay News) -- In a living systematic review and...